<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550652</url>
  </required_header>
  <id_info>
    <org_study_id>WA29748</org_study_id>
    <secondary_id>2015-002022-39</secondary_id>
    <nct_id>NCT02550652</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This Phase II study will compare the efficacy and safety of obinutuzumab plus mycophenolate
      mofetil (MMF)/mycophenolic acid (MPA) with placebo plus MMF/MPA in participants with
      proliferative LN.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 13, 2015</start_date>
  <completion_date type="Anticipated">December 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined Complete Renal Response (CRR)</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined Overall Response</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Protocol Defined Overall Response Over the Course of 52 Weeks</measure>
    <time_frame>From Baseline (Day 1) to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined Partial Renal Response (PRR)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined CRR</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Protocol Defined CRR Over the Course of 52 Weeks</measure>
    <time_frame>From Baseline (Day 1) to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Anti-Double Stranded Deoxyribonucleic Acid (Anti-dsDNA) Levels</measure>
    <time_frame>Baseline, Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C3 Levels</measure>
    <time_frame>Baseline, Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C4 Levels</measure>
    <time_frame>Baseline, Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined Modified CRR (mCRR1)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined Second mCRR (mCRR2)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve Protocol Defined Third mCRR (mCRR3)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Score</measure>
    <time_frame>Baseline (Day 1), Weeks 4, 12, 24, 36, 52/early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Circulating CD19-Positive B-Cell Levels</measure>
    <time_frame>Baseline, Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From Baseline up to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating T-Cell Levels</measure>
    <time_frame>Baseline (Day 1), Weeks 2, 4, 12, 24, 36, 52, 76, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Neutrophil Levels</measure>
    <time_frame>Baseline (Day 1), Weeks 2, 4, 12, 24, 36, 52, 76, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Antibody Titers to Mumps, Rubella, Varicella, Tetanus, Influenza, and Streptococcus pneumoniae</measure>
    <time_frame>Weeks 24, 52/early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibody (ADA) to Obinutuzumab</measure>
    <time_frame>Baseline (Day 1), Weeks 24, 52, 76, 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Obinutuzumab</measure>
    <time_frame>Pre-infusion (within 30 minutes [min] prior to start of infusion), end of infusion (infusion duration: 255 min for first dose and 195 min for subsequent doses) on Days 1, 15, 168, 182; Days 28, 84, 252, 364, 532, 728</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of Obinutuzumab</measure>
    <time_frame>Pre-infusion (within 30 min prior to start of infusion), end of infusion (infusion duration: 255 min for first dose and 195 min for subsequent doses) on Days 1, 15, 168, 182; Days 28, 84, 252, 364, 532, 728</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance of Obinutuzumab</measure>
    <time_frame>Pre-infusion (within 30 min prior to start of infusion), end of infusion (infusion duration: 255 min for first dose and 195 min for subsequent doses) on Days 1, 15, 168, 182; Days 28, 84, 252, 364, 532, 728</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution Under Steady State (Vss) of Obinutuzumab</measure>
    <time_frame>Pre-infusion (within 30 min prior to start of infusion), end of infusion (infusion duration: 255 min for first dose and 195 min for subsequent doses) on Days 1, 15, 168, 182; Days 28, 84, 252, 364, 532, 728</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Plasma Half-Life (t1/2) of Obinutuzumab</measure>
    <time_frame>Pre-infusion (within 30 min prior to start of infusion), end of infusion (infusion duration: 255 min for first dose and 195 min for subsequent doses) on Days 1, 15, 168, 182; Days 28, 84, 252, 364, 532, 728</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated based on tolerability to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated based on tolerability to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil/Mycophenolic Acid</intervention_name>
    <description>MMF/MPA will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <other_name>Gazyva, GA101, RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone IV will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered as per schedule specified in the respective arm.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Systemic Lupus Erythematosus (SLE), according to current American College
             of Rheumatology (ACR) criteria

          -  Diagnosis of International Society of Nephrology/Renal Pathology Society (ISN/RPS)
             2003 Class III or IV LN as evidenced by renal biopsy performed within 6 months prior
             to or during screening. Participants may co-exhibit Class V disease in addition to
             either Class III or Class IV disease

          -  Proteinuria (urine protein to creatinine ratio) greater than (&gt;) 1.0

          -  For women who are not postmenopausal (greater than or equal to [&gt;/=] 12 months of
             non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or
             uterus): agreement to remain abstinent or use two adequate methods of contraception,
             including at least one method with a failure rate of less than (&lt;) 1 percent (%) per
             year, during the treatment period and for at least 18 months after the last dose of
             study drug

          -  For men: agreement to remain abstinent or use a condom plus an additional
             contraceptive method that together result in a failure rate of &lt;1% per year during the
             treatment period and for at least 12 months after the last dose of study drug and
             agreement to refrain from donating sperm during this same period

        Exclusion Criteria:

          -  Retinitis, poorly controlled seizure disorder, acute confusional state, myelitis,
             stroke or stroke syndrome, cerebellar ataxia, or dementia that is currently active and
             resulting from SLE

          -  Presence of rapidly progressive glomerulonephritis

          -  Severe renal impairment as defined by estimated Glomerular Filtration Rate (GFR) &lt;30
             milliliters per minute (mL/min) or the need for dialysis or renal transplant

          -  Greater than 50% of glomeruli with sclerosis on renal biopsy

          -  Treatment with cyclophosphamide or calcineurin inhibitors within the 3 months prior to
             randomization

          -  Unstable disease with thrombocytopenia or at high risk for developing clinically
             significant bleeding or organ dysfunction requiring therapies such as plasmapheresis
             or acute blood or platelet transfusions

          -  History of severe allergic or anaphylactic reactions to monoclonal antibodies or known
             hypersensitivity to any component of the obinutuzumab infusion

          -  Significant or uncontrolled medical disease in any organ system not related to SLE or
             LN, which, in the investigator's opinion, would preclude participant participation

          -  Concomitant chronic conditions, excluding SLE, (e.g., asthma, Crohn's disease) that
             required oral or systemic steroid use in the 52 weeks prior to screening

          -  Previous treatment with an anti-cluster of differentiation (CD20)-targeted therapy
             within 12 months

          -  Previous treatment with a biologic B-cell-targeted therapy (other than anti-CD20)
             within 6 months of randomization

          -  Known intolerance to MMF or MPA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wallace Rheumatic Study Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Southern California Permanente Medical Group/ Research and Evaluation/Rheumatology</name>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Kidney Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Uni ; Division of Rheumatology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA State Univ; Medicine</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suny Downstate Medical Center; Rheumatology</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore - Long Island Jewish Hospital Health System; Rheumatology &amp; Allergy- Clinical Immunology</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University; Division of Nephrology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Center For Arthritis Therapy &amp; Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cemic; Haematology</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SER da Bahia - Serviços Especializados em Reumatologia</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40150-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Internacional de Pesquisa; Reumatologia</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74110010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFMG; Centro de Pesquisa Clínica</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Mineiro de Pesquisa - CMIP</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <zip>36036-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Scribner.</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80440-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Serviços Médicos S/S</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Oswaldo Ramos - UNIFESP; Nefrologia</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04039-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica De La Costa</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Ignacio</name>
      <address>
        <city>Bogota</city>
        <zip>000472</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo De Fractura; Rheumatology</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin-Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinica Catolica</name>
      <address>
        <city>Goicoechea</city>
        <zip>10801</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL HENRI MONDOR; SERVICE DE Nephrologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez; Internal Medicine</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital europeen Marseille; Service de medecine interne</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere; Service de Medecine Interne Ii</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat Claude Bernard; Nephrologie</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil; Clinique Medicale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil; Service de Nephrologie &amp; D'Immunologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe; Dept of Medicine B</name>
      <address>
        <city>Beer Yaakov</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center; Rheumatology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnei Zion Medical Center; Rheumatology</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Center; Rheumatology</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center; Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky / Ichilov Hospital; Rheumatology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I; Dipartimento Medicina Interna e Specialità Mediche</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco; entro di Ricerche di Immunopatologia e Documentazione su Malattie Rare</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova; Dipartimento di Medicina - UOC di Reumatologia</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion y Biomedicina de Chihuahua, Sociedad Civil</name>
      <address>
        <city>Chichuahua</city>
        <state>Chihuahua</state>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Clínica de Morelia S.C.</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)</name>
      <address>
        <city>Culiacán Rosales</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia</name>
      <address>
        <city>Guadalajara</city>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica Y Clinica S.C.; Reumatologia</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morales Vargas Centro de Investigacion S.C.</name>
      <address>
        <city>Leon</city>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel</name>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General De Mexico; Rheumatology</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán</name>
      <address>
        <city>Mexico City</city>
        <zip>Tlalpan 14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trial Labs</name>
      <address>
        <city>Panama</city>
        <zip>081500551</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecología y Reproducción</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Delgado; Clinica Delgado</name>
      <address>
        <city>Miraflores</city>
        <zip>15074</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas/Hospital Maria Auxiliadora</name>
      <address>
        <city>San Juan de Miraflores</city>
        <zip>15801</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia; Rheumatology</name>
      <address>
        <city>San Martin de Porres</city>
        <zip>15102</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba; Servicio de Reumatologia</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge; Servicio de Nefrologia</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Puigvert; Servicio de Nefrologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron; Servicio de Medicina Interna</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial; Servicio de Nefrologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitaro Gregorio Marañon ;Servicio de Nefrologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya; Servicio de Reumatologia</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

